ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease

First study of ADX48621 in male and female Parkinson's disease patients with levodopa-induced dyskinesia. Four weeks, double-blind, placebo-controlled dose titration from 50 mg once daily up to 100 mg three times daily, at the start of week 4. Safety and tolerability assessed by adverse events enquiry, heart rate and blood pressure, 12-lead ECG, haematology and biochemistry. Efficacy assessments include Abnormal Involuntary Movement Scale (AIMS), Unified Parkinson's Disease rating Scale (UPDRS) patient PD symptom diaries, Hospital Anxiety Depression Scale (HADS), patient and clinician global impression of change in PD and dyskinesia (PGIC and CGIC).

Inclusion criteria

• outpatient with idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnosis Criteria (UKPDSBBCDC)
• experiences moderately disabling dyskinesia (screening visit UPDRS 33 score≥2)
• has an mAIMS score at baseline ≥ 7 with a score ≥ 3 in at least one body area

Exclusion criteria

• surgical treatment for Parkinson's disease (e.g. Deep Brain Stimulation, within the last year or planned during the study)
• unstable co-existing psychiatric disease including cognitive impairment that, according to the Investigator, could interfere with the conduct of the study
• has a history of a significant medical condition that may affect the safety of the patient or preclude adequate participation in the study.
• is pregnant or breast-feeding. Female patients who are of child-bearing potential must be using adequate contraceptive methods (e.g. oral contraceptive, double-barrier method, intra-uterine device, intra-muscular hormonal contraceptive), and have a negative pregnancy test at Screening

Other protocol-defined inclusion and exclusion criteria may apply